This Phase II study is trying to understand the effectiveness of a targeted therapy drug (cobolimab) in combination with another type of targeted therapy (dostarlimab) and chemotherapy (docetaxel) in people with advanced non-small cell lung cancer.
This trial is treating patients with advanced non-small cell lung cancer that has progressed prior anti-PD(L)1 therapy and chemotherapy.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Commercial Sponsor
GlaxoSmithKline
Summary
This is a randomised trial with two experimental arms and an active comparator arm. Participants in Experimental Arm 1 will receive cobolimab + dostarlimab + docetaxel, all administered intravenously. Participants in Experimental Arm 2 will receive dostarlimab + docetaxel, both administered intravenously. Participants in the Active Comparator Arm will receive only docetaxel, administered intravenously.
Recruiting Hospitals Read More